CA9 and familial pancreatic carcinoma: Previous studies with CA IX inhibitor U-104, which is currently undergoing clinical trials for metastatic pancreatic cancer treatment in combination with gemcitabine, also showed that it could influence CA IX positive (hypoxic) MDA-MB-231 cell migration [10].